Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allergy immunotherapy - Roxall Medizin

Drug Profile

Allergy immunotherapy - Roxall Medizin

Alternative Names: Allergovac depot Olea; Allergovac grass pollen; Allergovac grass pollen depot; Allergovac Poliplus; BIA 14-2964; Olea europaea extract - Bial; PHLEUM PRATENSE POLLEN; SULGEN Spray Dermatophagoides pteronyssinus; SULGEN Spray Phleum pratense

Latest Information Update: 22 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bial
  • Developer BIAL; ROXALL Medizin GmbH
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Allergic rhinoconjunctivitis
  • Phase II Seasonal allergic rhinitis

Most Recent Events

  • 16 Mar 2023 Phase-II/III clinical trials in Allergic rhinoconjunctivitis (In adults) in Germany (Sublingual) (EudraCT2021-005169-41)
  • 07 Feb 2023 Roxall Medizin GmbH initiates a phase-II trial in Seasonal allergic rhinitis (In adults) in Germany (Sublingual) (EudraCT2021-002881-42)
  • 07 Feb 2023 Roxall Medizin GmbH initiates a phase-II trial in Allergic rhinoconjunctivitis (In adults) in Germany (Sublingual) (EudraCT2021-002881-42)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top